Markets:

Overview

News

Currencies

International

Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

111.82 +2.04 (+1.86%)

Streaming Delayed Price Updated: 2:17 PM EDT, Jun 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Protagonist Therapeutics (NASDAQ:PTGX) Shows Technical Strength and High Growth Momentum ↗

June 13, 2026

Via Chartmill

Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗

May 29, 2026

This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.

Via The Motley Fool

Topics Regulatory Compliance

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗

May 29, 2026

This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.

Via The Motley Fool

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗

May 18, 2026

This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.

Via The Motley Fool

Topics Regulatory Compliance

BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In ↗

October 14, 2025

Via Stocktwits

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗

May 18, 2026

Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.

Via The Motley Fool

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗

May 18, 2026

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

Via The Motley Fool

Topics ETFs Regulatory Compliance

FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market

March 23, 2026

In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of...

Via MarketMinute

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗

March 21, 2026

This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.

Via The Motley Fool

Topics Regulatory Compliance

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗

March 21, 2026

Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.

Via The Motley Fool

Topics Regulatory Compliance

This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗

March 20, 2026

RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.

Via The Motley Fool

Topics Regulatory Compliance

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.

Via The Motley Fool

Topics Regulatory Compliance

Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance ↗

February 16, 2026

This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance.

Via The Motley Fool

Topics Regulatory Compliance

Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes ↗

February 01, 2026

The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but the reason was for something very simple.

Via The Motley Fool

Topics Regulatory Compliance

"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape

January 15, 2026

As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Protagonist (PTGX) Earnings Call Transcript ↗

November 27, 2025

Protagonist (PTGX) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

What 7 Analyst Ratings Have To Say About Protagonist Therapeutics ↗

October 28, 2025

Via Benzinga

Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million ↗

October 23, 2025

Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million

Via The Motley Fool

Topics Energy

Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million ↗

October 23, 2025

Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million

Via The Motley Fool

Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million ↗

October 21, 2025

Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million

Via The Motley Fool

Topics Regulatory Compliance

2 Top Dividend Kings Every Income Investor Should Own ↗

October 20, 2025

These companies pay durable and steadily rising dividends.

Via The Motley Fool

Topics Bonds

Johnson & Johnson's M&A Strategy Is the Real Story for Investors ↗

October 18, 2025

Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.

Via MarketBeat

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook ↗

October 14, 2025

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes.

Via Benzinga

Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print ↗

October 14, 2025

Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.

Via Stocktwits

Topics Government World Trade

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch ↗

October 13, 2025

Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.

Via Benzinga

FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy ↗

October 13, 2025

FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's overall benefit.

Via Benzinga

Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears ↗

October 13, 2025

U.S. markets were rattled on Friday after President Trump reignited trade tensions with China, triggering the sharpest sell-off since April. Tech and AI stocks led the decline, while gold and...

Via Chartmill

Topics Artificial Intelligence Government World Trade

Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today ↗

October 10, 2025

The company could soon be swallowed by a very large peer -- which also happens to be a business partner.

Via The Motley Fool

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

October 10, 2025

Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 10, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.